Cencora (COR) Stock Price, News & Analysis

Company Overview

Cencora, formerly known as AmerisourceBergen until its rebranding in early 2024, is a global pharmaceutical sourcing and distribution company that provides a broad range of services to healthcare providers, pharmaceutical manufacturers and patients. Through its extensive logistics network, Cencora distributes branded, generic and specialty pharmaceuticals, as well as over-the-counter medical products, vaccines and biosimilars. The company’s offerings extend to value-added services such as patient assistance programs, infusion support, and consulting for regulatory and supply-chain optimization.

The company operates through two primary segments: the global distribution business, which supplies drugs and related healthcare products to hospitals, retail pharmacies and long-term care facilities; and the specialty solutions business, which focuses on high-growth areas such as oncology, rare diseases and complex therapies. In addition to traditional wholesale distribution, Cencora delivers hub services, reimbursement support and specialty pharmacy services designed to improve patient outcomes and streamline treatment pathways.

Founded in 2001 via the merger of Bergen Brunswig and AmeriSource Health, Cencora has grown through strategic acquisitions and partnerships to strengthen its position in key markets. Over the years, the company has expanded its footprint beyond North America to serve customers in Europe, Asia Pacific and other international regions. Its state-of-the-art distribution centers and cold-chain capabilities ensure secure, efficient delivery of sensitive pharmaceutical products.

Headquartered in Chesterbrook, Pennsylvania, Cencora is led by Chief Executive Officer Steven H. Collis, who has steered the organization through significant industry shifts and its recent corporate rebranding. Under his leadership, the company continues to focus on innovation, operational excellence and collaboration with healthcare stakeholders to address global public health challenges and support the evolving needs of patients and providers.

Key Stats

• Today's Range: $314.70 to $319.68
• 50-Day Range: $278.18 to $314.14
• 52-Week Range: $221.95 to $319.68
• Volume: 717,800 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $61.60 billion
• P/E Ratio: 32.66
• Dividend Yield: 0.69%
• Price Target: $320.00
• Consensus Rating: Moderate Buy

Cencora Stock Analysis - MarketRank™

Cencora scored higher than 90% of companies evaluated by MarketBeat, and ranked 90th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cencora has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Cencora is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Cencora has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.82%

Earnings Growth

Earnings for Cencora are expected to grow by 9.82% in the coming year, from $15.37 to $16.88 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cencora is 32.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 231.08.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cencora is 32.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.43.

Price to Earnings Growth Ratio

Cencora has a PEG Ratio of 1.45. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Cencora has a P/B Ratio of 78.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.61% of the float of Cencora has been sold short.

Short Interest Ratio / Days to Cover

Cencora has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in Cencora has recently increased by 9.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Cencora has a dividend yield of 0.71%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Cencora has been increasing its dividend for 15 years.

Dividend Coverage

The dividend payout ratio of Cencora is 22.63%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Cencora will have a dividend payout ratio of 13.03% next year. This indicates that Cencora will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.1 / 5
• Environmental Score: -0.77

Percentage of Shares Shorted

3.61% of the float of Cencora has been sold short.

Short Interest Ratio / Days to Cover

Cencora has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in Cencora has recently increased by 9.12%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.18

News Sentiment

Cencora has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 34 news articles for Cencora this week, compared to 31 articles on an average week.

Search Interest

18 people have searched for COR on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.

MarketBeat Follows

8 people have added Cencora to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cencora insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,292,923.00 in company stock.

Percentage Held by Insiders

10.80% of the stock of Cencora is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.52% of the stock of Cencora is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

COR Stock Analysis - Frequently Asked Questions

How have COR shares performed this year?

Cencora's stock was trading at $224.68 at the start of the year. Since then, COR shares have increased by 41.0% and is now trading at $316.8550.

How were Cencora's earnings last quarter?

Cencora, Inc. (NYSE:COR) posted its earnings results on Wednesday, August, 6th. The company reported $4.00 earnings per share for the quarter, beating analysts' consensus estimates of $3.79 by $0.21. Cencora's quarterly revenue was up 8.7% compared to the same quarter last year.
Read the conference call transcript.

Does Cencora have any subsidiaries?

The following companies are subsidiaries of Cencora: Alliance Healthcare, H. D. Smith, St. Francis Group, PharMEDium Healthcare, MWI Veterinary Supply, World Courier, IntrinsiQ, and others.

Who are Cencora's major shareholders?

Top institutional investors of Cencora include Voya Investment Management LLC (0.19%), Assenagon Asset Management S.A. (0.18%), Wedge Capital Management L L P NC (0.05%) and Czech National Bank (0.03%). Insiders that own company stock include Walgreens Boots Alliance, Inc, Steven H Collis, Robert P Mauch, Robert P Mauch, Dermot Mark Durcan, Lazarus Krikorian, Silvana Battaglia, Elizabeth S Campbell, Gina Clark, Gina Clark, Leslie E Donato and Leslie E Donato.
View institutional ownership trends.

How do I buy shares of Cencora?

Shares of COR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cencora own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cencora investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Broadcom (AVGO), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

• Last Earnings: 8/06/2025
• Record date for 9/3 Dividend: 8/15/2025
• Ex-Dividend for 9/3 Dividend: 8/15/2025
• Dividend Payable: 9/03/2025
• Today: 10/10/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Health Care Distributors
• Current Symbol: NYSE:COR
• CIK: 1140859
• Web: www.amerisourcebergen.com
• Phone: (610) 727-7000
• Fax: 800-640-5221
• Employees: 46,000
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Cencora: $320.00
• High Price Target: $355.00
• Low Price Target: $280.00
• Potential Upside/Downside: +1.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $9.72
• Trailing P/E Ratio: 32.32
• Forward P/E Ratio: 20.44
• P/E Growth: 1.45
• Net Income: $1.51 billion
• Net Margins: 0.60%
• Pretax Margin: 0.81%
• Return on Equity: 267.36%
• Return on Assets: 4.31%

Debt

• Debt-to-Equity Ratio: 3.64
• Current Ratio: 0.90
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: $293.96 billion
• Price / Sales: 0.21
• Cash Flow: $20.11 per share
• Price / Cash Flow: 15.62
• Book Value: $4.04 per share
• Price / Book: 77.76

Miscellaneous

• Outstanding Shares: 193,880,000
• Free Float: 172,939,000
• Market Cap: $60.91 billion
• Optionable: Optionable
• Beta: 0.63